Ocular Therapeutix (OCUL) Notes Payables (2013 - 2023)

Ocular Therapeutix (OCUL) posted quarterly Notes Payables of $2.1 million for Q2 2023, down 74.87% on a QoQ basis from $8.3 million in Q1 2021.

Ocular Therapeutix (OCUL) Notes Payables (2013 - 2023) Analysis & Trends

Ocular Therapeutix has reported Notes Payables for 9 years, with the latest figure at $2.1 million in Q2 2023.

Notes Payables for Q2 2023 came in at $2.1 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $2.1 million (changed N/A YoY), and the FY2020 annual result was $8.3 million, changed N/A from the prior year.
Notes Payables eased to $2.1 million in Q2 2023, from $8.3 million in the prior quarter.
Over five years, Notes Payables peaked at $8.3 million in Q4 2020 and troughed at $2.1 million in Q1 2020.
A 3-year average of $5.2 million and a median of $5.2 million in 2020 frame the typical range for Notes Payables.
The largest YoY upside for Notes Payables was 299.71% in 2021 against a maximum downside of 299.71% in 2021.
A 3-year view of Notes Payables shows it stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then tumbled by 74.87% to $2.1 million in 2023.
Per Business Quant data, the three most recent Notes Payables figures were $2.1 million in Q2 2023, $8.3 million in Q1 2021, and $8.3 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Ocular Therapeutix	2.20 Bn	2.20 Bn	11.46 Mn

Download Data